Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

PATHOLOGY RESEARCH AND PRACTICE is a premier journal in the field of pathology and forensic medicine, published by Elsevier GmbH in Germany. With a rich publication history since 1978 and an impressive convergence period extending to 2024, this journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of pathological processes. It holds notable rankings, including Q3 in Cell Biology and Q2 in Pathology and Forensic Medicine for 2023, reflecting its significance in the academic community. The journal aims to publish innovative research findings, reviews, and case studies, facilitating a deeper understanding of disease mechanisms and improving diagnostic practices. Authors and readers alike benefit from its reputable platform, noted for its challenging and rigorous peer-review process. By fostering a collaborative environment and providing open access options, PATHOLOGY RESEARCH AND PRACTICE continues to contribute meaningfully to the discourse within its respective fields, thereby appealing to a diverse audience of researchers, professionals, and students.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

GENOME BIOLOGY is a premier, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genomics, molecular biology, and bioinformatics. Accessible as an Open Access journal since 2000, it aims to disseminate high-quality, cutting-edge research that contributes to our understanding of genome biology's intricate mechanisms. The journal boasts an impressive impact, ranking 8th in Agricultural and Biological Sciences and 9th in Biochemistry, Genetics and Molecular Biology, highlighting its significance among scholars, professionals, and students alike. With a commitment to facilitating the exchange of invaluable scientific knowledge, GENOME BIOLOGY provides an important platform for discussions on evolutionary biology, genetic systems, and cell biology, contributing to the advancement of these dynamic disciplines.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.